Secondary
diarrhea, birth anomaly, pain, dizziness, nausea,, colitis
ADVERSE EVENTS, PRETERM PREMATURE RUPTURE OF MEMBRANES, ADVERSE EFFECTS, SECONDARY, PRETERM LABOR, COLITIS
The secondary endpoints included the proportion of patients with persisting anemic symptoms (epigastric pain, weakness, dizziness) at two weeks after initial therapy, incidence of any maternal adverse events (such as diarrhea, nausea, vomiting, colitis and drop-out from adverse effects) following commencement of therapy, incidence of any fetal adverse events (such as preterm labor, preterm premature rupture of membranes, low birthweight or birth anomaly) following commencement of therapy, mean levels of renal function parameters (serum electrolyte, urea and creatinine) at two weeks after initial therapy and mean levels of liver function parameters (aspartate transaminase (AST); alkaline phosphatase (ALP); and alanine transaminase (ALT)) at two weeks after initial therapy. As safety variables, adverse events were monitored throughout the whole study period from the signature of the informed consent form up to the last visit.